Biomerica InFoods IBS Data to be Presented at the Upcoming Digestive Disease Week (DDW) 2024 Conference

• Collaborators at the University of Michigan will present new Data on InFoods IBS in the DDW Irritable Bowel Syndrome (IBS) Clinical Session
  

IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company at the forefront of innovative gastroenterology solutions, proudly announces that data from collaborators at the University of Michigan utilizing its groundbreaking inFoods IBS technologies will be presented in the IBS Clinical Session at the 2024 Digestive Disease Week (DDW) Annual Meeting in Washington DC. DDW is renowned as the world's premier scientific and clinical meeting for digestive disease health care professionals.

"We are excited that our technology will be prominently featured in a presentation at this year's DDW conference," said CEO Zack Irani. "The forthcoming presentation marks a significant milestone, contributing valuable data to the growing clinical evidence supporting the efficacy of the InFoods IBS technology."

Dr. William D. Chey, MD, AGAF, FACG, FACP, RFF Chief of Gastroenterology at the University of Michigan , stated: "The compelling data on InFoods underscores the potential for novel dietary interventions to alleviate symptoms for IBS sufferers."

Dr. Prashant Singh, MD, of the University of Michigan will present:

EFFICACY OF A NOVEL, DISCRIMATORY P-VALUE BASED, IGG ASSAY-GUIDED ELIMINATION DIET BY IBS SUBTYPE: RESULTS FROM A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, SHAM-CONTROLLED STUDY

DDW 2024 will take place at the Walter E. Washington Convention Center in Washington, D.C., from May 18 to 24, 2024. Further details regarding presentation schedules will be provided closer to the conference date.

About inFoods
The inFoods IBS test is designed to assess a patient’s above normal immunoreactivity to specific foods utilizing a simple finger-stick blood sample. Instead of difficult to manage broad dietary restrictions, physicians can now use the inFoods IBS information to make targeted, patient-specific recommendations about trigger foods that, when removed from the diet, may alleviate IBS symptoms such as pain, bloating, diarrhea and constipation. The inFoods IBS test and clinical outcomes were studied at several prominent centers including Mayo Clinic, Beth Israel Deaconess Medical Center Inc. - a Harvard Medical School Teaching Hospital, Houston Methodist Hospital, and the University of Michigan. The clinical results for improvement in the Abdominal Pain Intensity (API) responder endpoint of >30% reduction in pain, for IBS patients in the treatment diet arm was greater than patients in the placebo diet arm (p-value of 0.0246). The improvement for patients in the treatment arm versus the placebo arm is considered clinically significant and for certain endpoints is similar and, in some cases, better than the current drugs in the market. Further information about Biomerica’s patented inFoods Technology Platform can be found at: https://biomerica.com/inFoods/our-technology/.